The European Agency for the Evaluation of Medicinal Products
Evaluation of Medicines for Human Use

24 January 2002
CPMP/197/02

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS
15 - 17 JANUARY 2002 PLENARY MEETING
MONTHLY REPORT

The Committee for Proprietary Medicinal Products (CPMP) held its 78th plenary meeting from 15 to 17 January 2002.

Product related issues

Centralised procedures

The CPMP adopted four positive Opinions on initial marketing authorisation applications:

- For the triple application (three Part B) **BolusacPlus** and **MicardisPlus** (telmisartan - hydrochlorothiazide) from Boehringer Ingelheim International GmbH, and **PritorPlus** (telmisartan - hydrochlorothiazide) from GlaxoSmithKline indicated for the treatment of essential hypertension in patients whose blood pressure is not adequately controlled on telmisartan alone. The CPMP adopted these opinions by consensus. The assessment review by the EMEA began on 24 April 2001 and the opinion was adopted on 17 January 2002, with an active review time of 146 days. For further details, please see the published Summaries of Opinion (CPMP/152/02, CPMP/108/02 and CPMP/153/02).
- A positive opinion for **Invanz** (ertapenem) (Part B) from Merck Sharp & Dohme Limited indicated for the treatment of the following bacterial infections in adults: intra-abdominal infections, community acquired pneumonia and acute gynaecological infections. The CPMP adopted the opinion by majority vote. The assessment review by the EMEA began on 26 December 2000 and the opinion was adopted on 17 January 2002, with an active review time of 211 days. For further details, please see the published Summary of Opinion (CPMP/3699/01).

The CPMP noted the withdrawal of one application (Part B) and adopted three lists of questions (three Part B) for initial marketing authorisation applications. The Committee heard two oral presentations and one oral clarification from applicants concerning ongoing procedures.

An overview of centralised procedures since 1995 is given in **Annex 1**. There are no medicinal products for which marketing authorisations have been granted by the European Commission since the CPMP plenary meeting in December 2001. The post-authorisation centralised procedures finalised during this meeting are summarised in **Annex 2**.

Referrals

Referral under Article 7(5) of Commission Regulation (EC) No 541/95, as amended

The CPMP noted two withdrawals of a referral for Arbitration under Article 7(5) of Commission Regulation (EC) No 541/95, as amended. These referrals for arbitration procedure on Lipidil-Ter/Apteor (fenofibrate) from the Laboratoire Fournier, were initiated by France and the procedure started in September 2001.

7 Westferry Circus, Canary Wharf, London, E14 4HB, UK
Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 84 16
E-mail: mail@emea.eu.int http://www.emea.eu.int

Referral under Article 30 of Directive 2001/83/EC (previously known as Article 11 of Council Directive 75/319/EEC, as amended)

Following a referral initiated by France under Article 11, the CPMP adopted by majority vote an opinion for a nationally authorised medicinal product, containing fluvoxamine, leading to a EU-wide harmonised SPC.

Scientific Advice procedures

The CPMP was informed of the outcome of the discussions of the Scientific Advice Review Group (SciARG) meeting, which was held on Monday 14 January 2002. For further details, please see **Annex 3**. Dr. R. Shah and Prof. H.G. Eichler, the two COMP Members nominated in December 2001 as COMP representatives for the SciARG, will from now on be attending the SciARG meetings regularly. They will be involved in all matters related to Protocol Assistance procedures.

Non-product related issues

CPMP Working Parties and Ad Hoc Groups

- The fourth meeting of the Working Parties' Chairpersons group took place on 15 January 2002 under the Chairmanship of Dr. D. Brasseur. As part of the topics addressed during the meeting, the group discussed the European Assessors training network, technical operational matters across Working Parties and preparation for the ICH Steering Committee meeting.
- The Quality, Biotechnology, Safety, Efficacy, Pharmacovigilance Working Parties' and Blood Product Working Group 2002-2003 work programmes were adopted by the CPMP and will be published on the EMEA Website.
- Dr D. Brasseur, Chairman of the Paediatric Expert Group (PEG) reported from the meeting held on 14th December 2001. During the meeting, the group received a presentation regarding the German paediatric initiative. Issues relating to paediatric formulations (extemporaneous preparations in hospital pharmacies when an appropriate dosage from authorised finished products is not available), toxicological requirements, methodological requirements for small sample size, pharmacovigilance tools and pharmacokinetic studies to update the CPMP guideline were discussed. The next meeting will be held on 22 February 2002 in conjunction with the International Federation of Associations of Pharmaceutical Physicians meeting.
- A multidisciplinary Vaccines Expert Group (VEG) was put in place in December 2001. At that meeting the CPMP agreed on the mandate and the composition of the Expert Group, which will involve representatives from other Working Parties e.g. Biotechnology, Safety and Efficacy Working Parties. The chairman of the VEG is Dr. R. Dobbelaer.

The Committee was also informed of upcoming Ad Hoc Expert Groups' meetings:

- Ad Hoc Expert Group on comparability of Biotechnology products: pre-clinical and clinical aspects, under the Chairmanship of Dr. M. Toivonen scheduled to be held on 18 January 2002;
- Ad Hoc Expert Group on Xenogeneic cell therapy, under the Chairmanship of Dr. P. Kurki scheduled to be held on 5 February 2002;
- Ad Hoc Expert Group on Gene Therapy, under the Chairmanship of Dr. Tsang, scheduled to be held on 11 February 2002.

An overview of guidance documents adopted during the meeting or released for consultation to Interested Parties is attached as **Annex 4**.

Organisational Matters

- Following the workshop with Interested Parties held on 11 December 2001, the "Guideline on the acceptability of invented names for human medicinal products processed through the centralised procedure – (CPMP/328/98 rev. 3)" (see **Annex 4**) was endorsed by the invented Name Review Group (NRG) and thereafter adopted by the CPMP and will be published on the EMEA website. The

NRG held its 25th meeting on Monday 14 January 2002 and the conclusions of the group were subsequently adopted by the CPMP.

- The 10th meeting of the CPMP Ad Hoc Group on Organisational Matters (ORGAM) was held on 14 January 2002. The January 2002 ORGAM meeting started with an overall review of the ORGAM 2001 achievements. The Members agreed that during 2002 the activities initiated in 2001 should continue. In addition EMEA/CPMP transparency and communication policies as well as pharmacovigilance procedures should be strengthened and further developed. Finally, the Members agreed that the ORGAM meetings will take place every other month in 2002.

PROCEDURAL ANNOUNCEMENT

The CPMP adopted the CPMP meetings calendar meeting dates for 2003 and 2004

Calendar for CPMP meetings in 2003	
Month	CPMP Dates
January	21, 22, 23
February	18, 19, 20
March	18, 19, 20
April	23, 24, 25
May	20, 21, 22
June	24, 25, 26
July	22, 23, 24
August[1)]	*19, 20, 21*
September	23, 24, 25
October	21, 22, 23
November	18, 19, 20
December	16, 17, 18

Calendar for CPMP meetings in 2004	
Month	CPMP Dates
January	20, 21, 22
February	24, 25, 26
March	23, 24, 25
April	20, 21, 22
May	25, 26, 27
June	22, 23, 24
July	27, 28, 29
August[1)]	*24, 25, 26*
September	14, 15, 16
October	19, 20, 21
November	16, 17, 18
December	14, 15, 16

[1)] dates for August are tentative

Mutual Recognition procedure

The CPMP noted the report from the MRFG which was held on 14 January 2002. This was the first meeting under the Spanish presidency, under the Chairmanship of Mrs Maria Luisa Garcia-Vaquero (for further details, please see **Annex 5**).

The 79th plenary meeting of the CPMP will be held from 19 to 21 February 2002.

Noël Wathion
Head of Unit
Post-Authorisation Evaluation of Medicines for Human Use
Tel. (+44-20) 74 18 85 92

This CPMP Monthly Report and other documents are available on the Internet at the following address: http://www.emea.eu.int.

EMEA CENTRALISED PROCEDURES

	1995-2001			2002			Overall Total
	Part A	Part B	Total	Part A	Part B	Total	
Scientific Advice	88	164	252	0	3	3	255
Follow-up to scientific advice	18	17	35	0	1	1	36
Protocol Assistance	0	2	2	2	0	2	4
Follow-up to Protocol Assistance	2	0	2	0	0	0	2

	1995-2001			2002			
	Part A	Part B	Total	Part A	Part B	Total	
Applications submitted	120	215	335	1	3	4	339
Withdrawals	15	45	60	0	1	1	61
Positive CPMP opinions	77	131	208	0	4	4	212[1]
Negative CPMP opinions[2]	1	4	5	0	0	0	5[3]
Marketing authorisations granted by the Commission	71	123	194	0	0	0	194[4]

	1995-2001			2002			Overall Total
	Part A	Part B	Total	Part A	Part B	Total	
Variations type I	448	806	1254	2	38	40	1294
Positive opinions, variations type II	285	362	647	10	11	21	668
Negative opinions, variations type II	1	6	7	0	0	0	7
Extensions (Annex II applications)	38	36	74	0	0	0	74

[1] 212 positive opinions corresponding to 164 substances
[2] In case of appeal the opinion will not be counted twice
[3] 5 negative opinions corresponding to 4 substances
[4] 194 marketing authorisations corresponding to 149 substances

OUTCOME OF THE JANUARY 2002 CPMP MEETING IN RELATION TO CENTRALISED APPLICATIONS IN THE POST-AUTHORISATION PHASE

Opinions for Type II Variation applications	
Number of Opinions	**Outcome**
10(SPC/PL update)	Positive by consensus
11(Pharmaceutical Aspects)	Positive by consensus

Opinion for Annual Re-Assessment applications		
Name of Medicinal Product (INN) MAH	**Outcome**	**Comments**
Remicade (infliximab) – Centocor B.V.	Positive by consensus	To remain under exceptional circumstances

Opinions for Renewal applications		
Name of Medicinal Product (INN) MAH	**Outcome**	**Comments**
Avonex (interferon beta-1a) Biogen France S.A.	Positive by consensus	To remain under exceptional circumstances
Refludan (lepirudin) – Aventis	Positive by consensus	-----

OUTCOME OF THE JANUARY 2002 CPMP MEETING IN RELATION TO SCIENTIFIC ADVICE PROCEDURES

Substance	Intended indications(s)	Topic				
		Type of Request		Pharma-ceutical	Pre-Clinical	Clinical
		New	Follow-up			
Biological	Fabry disease	X[1]				X
Biological	Graft versus host disease	X[1]				X
Biological	Anti-HIV treatment	X				X
Chemical	Type II diabetes	X				X
Chemical	Anti-HIV treatment		X			X
Chemical	Irritable bowel syndrome	X			X	

[1] Protocol Assistance requests.

In January 2002, the above mentioned six final Scientific Advice letters were adopted. The Committee accepted five new requests for Scientific Advice.

DOCUMENTS PREPARED BY THE CPMP WORKING PARTIES AND AD-HOC GROUPS ADOPTED DURING THE JANUARY 2002 CPMP MEETING

QUALITY WORKING PARTY

Reference number	Document	Status
CPMP/QWP/1719/00	Guideline on Medicinal Gases – Pharmaceutical Documentation	Adopted in January 2002

BIOTECHNOLOGY WORKING GROUP

Reference number	Document	Status
CPMP/BWP/2490/00	Cell Culture inactivated influenza vaccines – Annex to Note for Guidance on harmonisation of requirements for influenza vaccines	Adopted in January 2002

EFFICAY WORKING GROUP

Reference number	Document	Status
CPMP/EWP/1412/01	Concept paper for the development of the revision of the CPMP Note for Guidance on evaluation of new anti-bacterial medicinal products (CPMP/EWP/558/95) and the CPMP Note for Guidance on the pharmacodynamic section of the SPC for anti-bacterial medicinal products (CPMP/EWP/520/96)	Adopted in January 2002
CPMP/EWP/4151/00 draft 5	Points to consider on the requirements for clinical documentation for metered dose inhalers (MDI)	Released in January 2002 for 3 month consultation

BLOOD PRODUCTS WORKING GROUP

Reference number	Document	Status
CPMP/BPWG/3226/99	Core SPC for Human Plasma derived antithrombin	Adopted in January 2002
CPMP/BPWG/2220/99	Note for Guidance on the clinical investigation of plasma derived antithrombin products	Adopted in January 2002

ORGANISATIONAL MATTERS

Reference number	Document	Status
CPMP/328/98 rev.3	Guideline on the acceptability of invented names for human medicinal products processed through the centralised procedure	Adopted in January 2002

Report from the meeting held on 14 January 2002

General issues

Contact points for the Spanish MRFG/EUDRATRACK team:

NAME		TELEPHONE NUMBER	FAX NUMBER
Mª Luisa García-Vaquero	MRFG Chairperson	- 34 91 59615 61	-34 91 596 44 92 -34 91 596 40 69
Aurelio Fernandez Dominquez	EUDRATRACK Chairperson	- 34 91 59615 61	-34 91 596 44 92 -34 91 596 40 69
Mª Luisa Martinez Mora	Project Manager	- 34 91 596 40 53	-34 91 596 44 92 -34 91 596 40 69
Rita Quesada Ortells	Project Manager	- 34 91 596 19 84	-34 91 596 44 92 -34 91 596 40 69
Heidi de los Santos Real	Project Manager	- 34 91 596 12 75	-34 91 596 44 92 -34 91 596 40 69

MRP statistics 2001

Statistics regarding new applications in the MRP in the year 2001 according to the 5-level classification will be available on the Heads of Agencies Website by the end of January 2002.

Meeting schedule

The next MRFG meeting will be held on **18 February 2002**.

Mutual Recognition Monitoring

The MRFG noted that 56 new mutual recognition procedures were finalised during the month of December 2001, as well as 141 type I and 46 type II variations.

The status as of 31st December 2001 and for the period 1995–2001 of procedures under mutual recognition is as follows:

Year	Procedures from New applications finalised	Procedures from New applications in process	Procedures from Type I variations finalised	Procedures from Type I variations pending	Procedures from Type II variations finalised	Procedures from Type II variations pending	Arbitrations referred to CPMP
2001	443	101	1487	179	474	219	1 N.A. and 3 variations

The global status since 1st January 1995 is as follows (further detailed statistics can be found at the MRFG website):

Years	Procedures from New applications finalised	Procedures from Type I variations finalised	Procedures from Type II variations finalised	Arbitrations referred to CPMP
1995	10	16	17	1 N.A.
1996	84	49	73	1 N.A. and 1 variation
1997	146	101	163	1 N.A. and 1 variation
1998	182	339	222	1 N.A. and 4 variations
1999	228	671	301	2 N.A. and 2 variations
2000	306	1007	320	3 N.A. and 2 variations
2001	443	1487	474	1 N.A. and 3 variations
1995-2001	1399	3670	1570	10 N.A. and 13 variations

37 new procedures (regarding 49 products) started in December 2001. The categories of these procedures are as follows:

7 new active substances, including **2** multiple applications and **1** repeate use.

10 known active substances (already authorised in at least one member state), including **1** repeate use.

18 abridged applications including **4** multiple applications and **2** repeate use.

2 line extension applications.

The new procedures started this month relate to 9 full dossiers, 16 generics, 9 bibliographic applications and 3 for different use, route or dose.

The procedures consisted of 32 chemical substances, 2 biological – vaccines, 1 biological – blood product and 1 biological – others1.

25 of these procedures were prescription-only medicinal products in the reference Member State and 11 were Non-prescription (including OTC) medicinal products2. (1 is missing)

1. As considered by RMS.
2. In this category products are classified as prescription-only or Non-prescription (OTC) products when the RMS has approved them accordingly, although the legal status is not part of the Mutual Recognition Procedure.

Number of countries involved in the new applications procedures started in December 2001

Reference Member State (number of products involved in the procedure)	Number of CMSs involved in the procedure
DE (1)	1
DE (1)	7
DE (1)	7
DE (1)	2
DK (3)	14
DK (1)	9
DK (1)	9
DK (3)	15
DK (1)	2
FI (1)	4
FI (1)	2
FI (1)	1
FR (3)	12
FR (1)	4
IR (2)	4
IT (1)	14
IT (1)	2
IT (1)	2
NL (1)	6
NL (2)	3
NL (1)	1
NL (1)	1
NL (1)	16
NL (1)	1
NL (2)	2
NL (1)	1
NL (1)	1
SE (2)	11
SE (1)	2
SE (1)	6
SE (1)	16
SE (1)	16
SE (1)	1
SE (1)	1
UK (1)	15
UK (1)	2
UK (3)	11

All documents mentioned in this press release can be found at the MRFG website at the European Medicines Authorities Windows under the heading SOP.

Information on the above mentioned issues can be obtained by the presiding chair of the MRFG:

*Ms. Maria Luisa **GARCIA VAQUERO***
Agencia Española del Medicamento
c/Huertas 75
28014 MADRID - SPAIN

Phone: + 34 91 596 15 61
Fax: + 34 91 596 44 92
+ 34 91 596 40 69
e-mail: mgarciav@agemed.es

*Alternatively, you could visit the **MRFG web site** at the EUROPEAN NATIONAL MEDICINES AUTHORITIES WINDOW:*

http://heads.medagencies.org/